SSTRSSingle Solutions Tracking and Reporting System
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
[sup.68]Ga-DOTA peptides bind to SSTRs, in particular SSTR3 and SSTR5, both of which are usually overexpressed in neuroendocrine cells [24].
The choice to target somatostatin receptors is based on the analysis of expression levels of SSTRs in relatively small groups of human corticotroph pituitary adenomas ranging from 1 to 13 cases using RT-PCR [17-22] and the experience that had been gained with inhibitory substances in other endocrine tumors and diseases [21].
The role of somatostatin receptors (SSTRs) as therapeutic targets in pituitary adenomas is well established.[sup][11] SST analogs are reportedly effective in hormonal control of TSHomas and growth hormones (GH)-secreting adenomas.[sup][1],[12],[13]
analyzed 199 surgically removed G1-3 pNETs for their SSTRs expression (form type 1 to type 5) and its clinical significance.
The expression of 5-H[T.sub.1D]R had a negative correlation with somatostatin (SST) and SST receptors (SSTR), whereas the expression of 5-H[T.sub.2A]R did not have any correlation with either SST or any of the SSTRs; this suggests that increased expression of H[T.sub.1D]R in human islet cells, as observed in T2DM islet cells, leads to decreased expression of SST and its receptors.
Due to their neuroendocrine origin GEP-NENs express on their cell surface peptide receptors, such as somatostatin receptors (sstr) that can be used for diagnostic, prognostic, and therapeutic purposes [20].
Table 2 summarizes the different pathways of SSTR subtype activation.
Antibodies used to screen for SSTRs on parasite: Antibodies used to screen for SSTRs on S.
Somatostatin receptors (SSTRs) are variably expressed in neuroblastoma cell lines and tumors, as demonstrated by autoradiography, Western blot, immunohistochemistry, and RT-PCR techniques [17-19].
They exert biological effects by binding to G protein-coupled receptors known as somatostatin receptors (SSTR), mainly SSTR2 and SSTR5.
The leading clinical application area is oncology with targeted imaging of somatostatin receptors (SSTR), prostate specific membrane antigen (PSMA), integrin receptors, glucagon-like peptide 1 receptors (GLP1R), gastrin-releasing peptide receptors (GRPR), human epidermal growth factor receptor family (HER2), and pretargeted imaging of carcinoembryonic antigen (CEA) [1, 3, 5].